Search...
/
The Fly Cast
Press play to listen
Smarter market moves start here
Competitive Advantages
Dominant HIV Franchise: Gilead holds a leading position in the HIV treatment and prevention market, with highly effective and convenient regimens, providing a stable and substantial revenue base.
Robust Research & Development Pipeline: Consistent investment in R&D leads to a pipeline of potential new drugs across various therapeutic areas, particularly in oncology, antivirals, and inflammation, driving future growth.
Strong Intellectual Property Portfolio: A vast array of patents protects its existing blockbuster drugs and pipeline assets, ensuring market exclusivity and revenue generation for extended periods.
Risks
Patent Expirations and Generic Competition: Gilead's key blockbuster drugs face upcoming patent expirations, particularly within its established HIV franchise, which will lead to significant revenue declines due to generic market entry and increased competition.
Clinical Trial Failures: New drug candidates in Gilead's pipeline might fail to meet primary endpoints in clinical trials or demonstrate inadequate safety profiles, leading to substantial R&D write-offs, delayed market entry, and potential reputational damage.
Intense Market Competition: Gilead faces aggressive competition from other pharmaceutical and biotechnology companies across its core therapeutic areas, including HIV, oncology, and inflammation, potentially eroding market share for existing products and making new product launches challenging.
Tuesday
Jun 23, 7:50 AM
Over a week ago
Jun 15, 4:35 PM
Jun 12, 8:33 AM
Jun 5, 5:09 AM
Jun 2, 8:32 AM
May 27, 5:23 AM
May 22, 1:23 PM
May 22, 7:50 AM
May 21, 9:36 AM
May 21, 5:38 AM
May 20, 9:07 AM
May 20, 8:15 AM
May 20, 8:10 AM
May 13, 8:34 AM
May 10, 10:41 AM
May 8, 9:09 AM
May 7, 4:03 PM
May 7, 4:01 PM